A Study to Look at How Safe a New Medicine (NNC0491-6075) is in Healthy People and in Participants With High Levels of Fat in the Blood
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
106actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-07 | actual | When the study began enrolling |
| Primary completion | 2025-03-14 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-14 | actual | The whole study's end, after follow-up |
| First posted | 2023-08-07 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Dyslipidaemia
Interventions
- Drug: NNC0491-6075
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPart A (SAD): Number of treatment emergent adverse events (TEAEs)
measured From pre-dose (Day 1) to end of study (Day 110)
Part B (MAD): Number of treatment emergent adverse events (TEAEs)
measured From pre-dose (Day 1) to end of study (Day 131)
Part C (SAD): Number of treatment emergent adverse events (TEAEs)
measured From pre-dose (Day 1) to end of study (Day 110)
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed